Rationale for oncological surgery in multimodal cancer treatments;Rationnels de la chirurgie oncologique au sein d'un traitement multimodal des cancers

Journal de Chirurgie

Volumn 142, Issue 5, 2005, Pages 284-290

  Elias, O ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cancer; Miscellaneous; Multidisciplinary concertation; Treatment

Indexed keywords

EID: 26244458677     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(05)80931-7     Document Type: Article

References (44)

1. Vlems FA, Ruers TJ, Punt CJ, Wobbes TH, van Muijen GN. Relevance of disseminated tumour cells in blood and bone marrow of patients with solid epithelial tumours in perspective. Review. EJSO 2003;29:289-302.
2. Klein CA, Blankestein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Reithmuller G. Genetic heterogenicity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-689
3. Glaves D, Huben RP, Weiss L. Hematogenous dissemination of cells from human renal carcinomas. Br J cancer 1988;57:32-35.
4. Lindeman F, Schlimok G, Dirshedle P, Whitte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685-689.
5. Braun S, Pantel K, Muller P, Janni W, Hepp F, Fkentenich CR et al. Cytokeratin-positive cells in bone marrow and survival of patients with stage I, II, or III breast cancer. New Eng J Med 2000;342:525-533.
6. Hosh SB, Braun S, Pantel K. Characterisation of disseminated tumor cells. Sem Surg Oncol 2001;20:267-271.
7. Fisher B, Fisher ER. Barrier function of lymph node to tumor cells and erythrocytes. Cancer 1967;20:1907-1913.
8. Hermanek P, Giegl P, Dworak O. Two programms for examination of regional lymph nodes in colorectal carcinoma with regard to the new pN classification. Pathol Res Pract 1989;185:867-872.
9. Hansen R, Wolff N, Knuechel R, Ruschoff J, Hofstaedtter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg 1995;130:387-393.
10. Elias D, Cavalcanti A, Sabourin JC, Pignon JP, Ducreux M, Lasser PH. Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998;69:88-93.
11. Koo J, Fung K, Siu F et al. Recovery of malignant tumor cells from the right atrium during hepatic resection for hepatocellular carcinoma. Cancer 1983;52:1952-1956.
12. Slade NS, Simmons RL, Yunis E. Immunodepression after major surgery in normal patients. Surgery 1975;78:363-372.
13. Elias D, Farace F, Triebel F et al. Phase I-II randomized study on prehepatectomy recombinant inerleukin-2 in patients with metastasis carcinoma of the colon and rectum. J Am Coll Surg 1995;181:303-310.
14. Elias D, Lapierre V. Blood transfusion in cancer patients. Oncology Digest 1996;4:31-32.
15. Elias D. Répercussion de l'acte chirurgical sur la croissance des tumeurs. Ann Chir 1990;44:699-704.
16. Baker DG, Masterson TM, Pacer R, Constable WC, Wanebo H. The influence of the surgical wound on local recurrence. Surgery 1989;106:525-532.
17. Elias D. La chirurgie dite de réduction tumorale : mythe ou réalité ? J Chir (Paris) 1992;129:479-483.
18. Kavanaugh DY, Carbone DP. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am 1996;10:927-951.
19. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 2004;350:2343-2351.
20. Moertel CG, Fleming TH, MacDonald JS, Haller DG, Mayer RJ et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcioma. New Engl J Surg 1990;322:352-358.
21. Elias D, Ouellet JF. Intraperitoneal chemohyperthermia. Rationale, technique, indications, and results. Surg Oncol Clin North Am 2001;10:915-933.
22. Verwaal VC, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis from colorectal cancer. J Clin Oncol 2003;21:3737-3743.
23. 3. Elias D, Sideris L, Pocard M, Edé C, Ben Hassouna D, Ducreux M et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncology 2004;15:781-785.
24. Adam R, Pascal G, Castaing D, Azoulay D, Delvard V, Paule B et al. Tumor progression while on chemotherapy. A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052-1064.
25. Peeters C, de Geus LF, Wetphal JR, de Waal RM, Ruiter D, Wobbes T et al. Decrease in circulating anti-angiogenic factors after emoval of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery 2005;137:246-249.
26. Curtin JP, Shapiro F. Adjuvant therapy in gynecologic malignancies. Surg Oncol Clin North Am 1997;6:613-630.
27. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990;38:203-209.
28. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone, M, Barone R et al. Cytoreductive surgery combined with intraperitoneal chemotherapy for management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284-3292.
29. Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003;90:567-574.
30. Elias D, Maisonnette F, Druet-Cabanac M, Quellet JF, Guinebretière JM, Splielmann M, Delaloge S. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg 2002;185:158-164.
31. Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V et al. Hepatic and extrahepetic colorectal metastases : when resectable, their localization does not matter, but their total number has a prognostic impact. Ann Surg Oncol 2005 (in press).
32. Marie P, Clunet J. Fréquence des métastases viscérales chez les souris cancéreuses après ablation chirurgicale de leur tumeur. Bull Assoc Fr Etud Cancer 1910;3:19-23.
33. Murthy MS, Scanlon EF, Reid JR, Yang XF. Pre, peri, and postoperative chemotherapy for breast cancer: is one better than the other? J Surg Oncol 1996;61:273-277.
34. Nyssen-Meyer R, Kjellgren K, Malmio K, Manson B, Norin T. Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 1978;41:2088-2098.
35. de Roy DB, Wobbes T, Hendriks T, Klompmakers AA, de Boer HH. The effect of antineoplastic agents on the healing of small intestinal anastomosis in the rat. Cancer 1986;58:62-66.
36. van der Bilt J, Borel Rinks IH. Surgery and angiogenesis. Review. Biochimica et Biophysica Acta 2004;1654:95-104.
37. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El Otmany A et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncology 2002;13:267-272.
38. Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004;15:1558-1565.
39. Elias D, Lasser Ph, Rougier Ph, Nitenberg G, Théodore C, Lumbroso J. Early adjuvant intraportal chemotherapy after curative hepatectomy for colo-rectal liver metastases. A pilot study. Eur J Surg Oncol 1987;13:247-250.
40. Romano F, Cesana G, Berselli M, Piacentini MG, Caprotti R, Bovo G et al. Biological, histological, and clinical impact of preoperative IL2 administration in radically operable gastric cancer patients. J Surg Oncol 2004;88:240-247.
41. Elias D, Youssef O, Sideris L, Dromain C, Baton O, Boige V et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004;86:4-9.
42. Liotta LA, Espina V, Metha AI, Calvert V, Rosenblatt K, Geho D et al. Protein microarrays: meeting anatycal challenge for clinical applications. Cancer Cell 2003;3:317-325.
43. Paweletz CP, Charbonneau L, Bichsel VE, Simone NL, Chen T, Gillepsie JW et al. Reverse phase protein microarrays which capture diseaese progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20:1981-1989.
44. Petricoin EF, Ardekani AM, Hitt BA, Furaso BA, Steinberg SM et al. Use of proteomic paterns in serum to identify ovarian cancer. Lancet 2002;359:572-577.